Small-Angle X-ray Scattering for Pharmaceutical Applications - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Small-Angle X-ray Scattering for Pharmaceutical Applications
The author describes the development of small-angle X-ray scattering and analyzes its advantages in the characterization of drug-delivery systems and large molecules. This article is part of a special Analytical Technology issue.


Pharmaceutical Technology
Volume 34, pp. s32-s37

References

1. Fifty Years of X-ray Diffraction, P.P. Ewald, Ed. (A. Oosthoek's Uitgeversmaatschappij, Utrecht, 1962).

2. M. Lambert, Acta Crystallogr. 57 (1), 1–3 (2001).

3. J. Schurz, Colloid Polym. Sci. 273 (10), 994–995 (1995).

4. Small Angle X-ray Scattering, O. Glatter and O. Kratky, Eds. (Academic Press, London, 1982) 4f.

5. H. Schnablegger and Y. Singh, "A Practical Guide to SAXS," (Anton Paar, Graz, Austria, 2006).

6. J. Lake, Acta Crystallogr. 23 (2), 191 (1967).

7. G.R. Strobl, Acta Crystallogr. A 26 (3), 367–375 (1970).

8. M. Soliman, B.J. Jungnickel, and E. Meister, Acta Crystallogr., A, Found. 54 (5), 675–681 (1998).

9. C. Jeffries et al., J. Mol. Biol. 377 (4), 1186–1199 (2008).

10. H. Schnablegger, "Is Smearing An Issue?" (Anton Paar Graz, Austria, 2007).

11. M. Muthukumar, C.K. Ober, and E.L. Thomas, Science 277 (5330), 1225–1232 (1997).

12. G.M. Whitesides, J.P. Mathias, and C.T. Seto, Science 254 (5036), 1312–1319 (1991).

13. G.M. Whitesides and B. Crzybowski, Science 295 (5552), 2418–2421 (2002).

14. A.M. Edwards et al., Nat. Struct. Biol. 7 (11), 970–972 (2000).

15. R.F. Fischetti et al., J. Synchrotron Radiat. 10 (5), 398–404 (2003).

16. M. Hirai et al., J. Synchrotron Radiat. 9 (4), 202–205 (2002).

17. D.M. Tiede, R. Zhang, and S. Seifert, Biochemistry 41, 6605–6614 (2002).

18. R. Zhang, P. Thiyagarajan, and D.M. Tiede, J. Appl. Crystallogr. 33 (3), 565–568 (2000).

19. D.I. Svergun and M.H.J. Koch, Rep. Prog. Phys. 66 (10), 1735–1782 (2003).

20. J. Trewhella and J.K. Krueger, Methods Mol. Biol. 173, 137–159 (2002).

21. P. Chacon et al., Biophys. J. 74 (6), 2760–2775 (1998).

22. P. Chacon et al., J. Mol. Biol. 299 (5), 1289–1302 (2000).

23. D. Svergun, Biophys. J. 76 (6), 2879–2886 (1999), erratum in 77, (5), 2896–2896 (1999).

24. G. Fritz, A. Bergmann, and O. Glatter, J. Chem. Phys. 113 (21), 9733–9740 (2000).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here